DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Switzerland
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
KURN logo

Kuros Biosciences AG Stock Price

SWX:KURN Community·CHF 722.8m Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 25 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

KURN Share Price Performance

CHF 18.22
-5.28 (-22.47%)
​
CHF 32.80
Fair Value
CHF 18.22
-5.28 (-22.47%)
44.5% undervalued intrinsic discount
CHF 32.80
Fair Value
Price CHF 18.22
AnalystConsensusTarget CHF 32.80
Tue, 16 Dec 25
Fair ValueCHF 32.80
Share Pricen/a

KURN Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value CHF 32.8 44.5% undervalued intrinsic discount

Minimally Invasive Spine Procedures And Global Expansion Will Drive Long-Term Opportunity

0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
KURN logo
Kuros Biosciences
44.5% undervalued intrinsic discount

Minimally Invasive Spine Procedures And Global Expansion Will Drive Long-Term Opportunity

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Published 16 Dec 2025
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
KURN logo

Minimally Invasive Spine Procedures And Global Expansion Will Drive Long-Term Opportunity

Fair Value: CHF 32.8 44.5% undervalued intrinsic discount
8 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Exceptional growth potential with adequate balance sheet.

1 Risk
4 Rewards
View Full Analysis

Kuros Biosciences AG Key Details

US$174.9m

Revenue

US$23.9m

Cost of Revenue

US$151.1m

Gross Profit

US$142.2m

Other Expenses

US$8.9m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
0.22
86.37%
5.09%
1.6%
View Full Analysis

About KURN

Founded
2016
Employees
178
CEO
Christopher Fair
WebsiteView website
kurosbio.com

Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company provides MagnetOs Granules, an advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold uses to fill bony voids for intervertebral disc space or posterolateral spine; and Attrax, a biphasic calcium phosphate bone grafts that mimic the porous and trabecular structure of cancellous bone, as well as checkmate licensing. The company was incorporated in 2016 and is headquartered in Schlieren, Switzerland.

Recent KURN News & Updates

Recent updates

No updates

Kuros Biosciences AG Competitors

PPGN logo

PolyPeptide Group

Symbol: SWX:PPGN
Market cap: CHF 1.5b
SKAN logo

SKAN Group

Symbol: SWX:SKAN
Market cap: CHF 1.4b
IDIA logo

Idorsia

Symbol: SWX:IDIA
Market cap: CHF 1.3b
CMHC logo

Cosmo

Symbol: SWX:CMHC
Market cap: CHF 942.0m
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide